Ann: Promising Results CAPRA Melanoma Trial expand to 50 patients, page-3

.... and not only that, Montrachet, the effectiveness of the combination in late stage sufferers (those previously given up as dead) is 83%.

And, there is yet another upside.... Grade 3 or higher treatment related adverse events is 10.1% in Keytruda alone, BUT is reduced to ZERO when combined with Cavatak!

It should make Cavatak worth heaps (imho)... heaps. Wake up market... and wake up Merck!